Global Preclinical Imaging Market, By Modality (Optical Imaging Systems, Preclinical Nuclear Imaging Systems, Micro-magnetic Resonance Imaging Systems, Micro-Ultrasound Systems, Micro-computed Tomography Systems, Preclinical Photoacoustic Imaging Systems and Preclinical Magnetic Particle Imaging (MPI) Systems), Reagents (Preclinical Optical Imaging Reagents, Preclinical Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents and Preclinical CT Contrast Agents), End Users (Hospital, Diagnostics Center, Others) – Industry Trends and Forecast to 2029.
Global Preclinical Imaging Market Analysis and Size
Preclinical imaging has become a significant technique for biological discoveries over the last decade. In the post-genomic age, high-frequency micro-ultrasound has steadily grown as a quick and relatively inexpensive imaging tool for researching normal development and human disease models in small animals. Consequently, the market is projected to show substantial growth over the forecasted period.
- Global Preclinical Imaging Market was valued at USD 910.4 million in 2021 and is expected to reach USD 1529.49 million by 2029, registering a CAGR of 6.70% during the forecast period of 2022-2029. The “micro ultrasound” accounts for the largest modality segment in the preclinical imaging market within the forecasted period. It is a miniature version of ultrasound that basically has a wider range of applications in research activities for small animal models, which boosts the techniques' efficacy. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Preclinical Imaging Market Definition
Preclinical imaging is a multidisciplinary field encompassing molecular biology, chemistry, computer science, engineering, and medicine. It can recognize and monitor physiological or pathological processes in living creatures at the cellular or molecular level non-invasive and real-time. In the clinical care of many diseases, multimodal preclinical imaging can increase doctors' ability to perform screening, surveillance, staging, prognosis, planning and therapy guiding, monitoring therapy efficacy, and assessing recurrence.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2019 - 2014)
Revenue in USD Million, Volumes in Units, Pricing in USD
By Modality (Optical Imaging Systems, Preclinical Nuclear Imaging Systems, Micro-magnetic Resonance Imaging Systems, Micro-Ultrasound Systems, Micro-computed Tomography Systems, Preclinical Photoacoustic Imaging Systems and Preclinical Magnetic Particle Imaging (MPI) Systems), Reagents (Preclinical Optical Imaging Reagents, Preclinical Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents and Preclinical CT Contrast Agents), End Users (Hospital, Diagnostics Center, Others)
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa
Market Players Covered
PerkinElmer, Inc. (U.S.), Bruker (U.S.), FUJIFILM Holdings Corporation (Japan), Mediso Ltd. (Hungary), MILabs B.V. (Netherlands), MR Solutions (U.K.), LI-COR Inc., (U.S.), Aspect Imaging Ltd (Israel), TriFoil Imaging Inc., (U.S.), Danaher (US.), Siemens (Germany), Abbott (U.S.), F. Hoffmann-La Roche Ltd., (Switzerland), Bio-Rad Laboratories, Inc (U.K)., EKF Diagnostics (U.K), ?NIHON KOHDEN CORPORATION (Japan), and Thermo Fisher Scientific Inc. (U.S.)and Miltenyi Biotech (Germany), among others.
Preclinical Imaging Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:
- Increased Demand for Imaging Techniques
The surging demand for non-invasive small animal imaging techniques is the most significant factor driving the growth for this market.
- Surging Initiatives for Funding and Investments
The increased public-private initiatives and funding for advanced research as well as to support preclinical research are also expected to accelerate the overall growth of the market. Furthermore, the huge investments to spread awareness about the use of pre-clinical devices are also expected to fuel market growth.
Moreover, the rising demand from veterinary hospitals and educational institutions also cushions the market’s growth within the forecasted period. The advanced research infrastructure is also projected to bolster the market's growth.
- Growing Technological Advancements
Moreover, the rate of technological advances leading to the development of hybrid imaging systems and the growing number of clinical research organizations (CROs) and companies adopting in-vivo imaging systems in preclinical research are estimated to generate lucrative opportunities for the market. The technological advancements in molecular imaging will further offer numerous growth opportunities for the market.
Restraints/Challenges Global Preclinical Imaging Market
- High Costs
On the other hand, the high installation and the operational costs is expected to obstruct market growth.
- Stringent Regulations
Also, the stringent regulatory framework governing preclinical research is projected to challenge the preclinical imaging market in the forecast period of 2022-2029.
The technical and procedural limitations associated with autonomous systems and requirement for clinical trial-based evidence are also estimated to hamper the market’s growth. Also, animal testing restrictions imposed by animal rights activists will also limit the market's overall growth.
This preclinical imaging market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the preclinical imaging market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Post Covid-19 Impact on Preclinical Imaging Market
The outbreak largely impacted the healthcare due to the postponement of non-essential medical services, limited availability of medical facilities/treatment centers, trade barriers and halt in various operations, reduced demand and supply chain disruptions amid the covid-19 outbreak.
However, the preclinical imaging market was positively affected due to the pandemic, as the emergence of this disease globally has generated a significant opportunity for companies in the worldwide preclinical imaging market. There has been a surge in interest in researching the virus and its effects on animals. The coronavirus, which is thought to have originated in animals, including bats, is being examined through the lens of numerous research lines. This has opened up new opportunities for players in the worldwide preclinical imaging industry.
- In March 2021, Veristat announced the acquisition of Switzerland-based SFL (Solutions for Life Sciences) for an undisclosed sum to strengthen its position in the European market. The acquisition would give access to an SFL team with substantial knowledge encompassing a variety of therapies in orphan disease and oncology exploring new treatments, which might integrate artificial intelligence, diagnostics, and devices, according to Veristat, a CRO based in Southborough, Massachusetts. The SFL's experience in the EU, the United Kingdom, and the Swiss healthcare systems, according to the business, means profit for a US corporation wishing to enter those markets.
- In Feburary 2022, FUJIFILM VisualSonics, a global producer of ultra-high-frequency (UHF) ultrasound imaging systems, has announced a cooperation with PIUR IMAGING, the European leader in tomographic ultrasound imaging, to deliver UHF, three-dimensional (3D) ultrasound imaging technology to researchers and clinicians. The advancement in technology aids clinical research in a variety of areas, including MSK, vascular, dermatology, and neurology.
Global Preclinical Imaging Market Scope
The preclinical imaging market is segmented on the basis of modality, reagents and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Optical Imaging Systems
- Preclinical Nuclear Imaging Systems
- Micro-magnetic Resonance Imaging Systems
- Micro-Ultrasound Systems
- Micro-computed Tomography Systems
- Preclinical Photoacoustic Imaging Systems
- Preclinical Magnetic Particle Imaging (MPI) Systems
On the basis of modality, the preclinical imaging market is segmented into optical imaging systems, preclinical nuclear imaging systems, micro-magnetic resonance imaging systems, micro-ultrasound systems, micro-computed tomography systems, preclinical photoacoustic imaging systems and preclinical magnetic particle imaging (MPI) systems. The optical imaging systems are sub-segmented into bioluminescence/fluorescence imaging systems, standalone fluorescence imaging systems and optical + X-ray/optical + CT. The preclinical nuclear imaging systems are sub-segmented into micro-PET systems, micro-SPECT systems and trimodality (SPECT/PET/CT) systems. The micro ultrasound is projected to register for the largest markets share over forecasted period as it is a miniature version of ultrasound which basically has a wider range of applications in research activities for small animal models, which boost the efficacy of the techniques.
- Preclinical Optical Imaging Reagents
- Preclinical Nuclear Imaging Reagents
- Preclinical MRI Contrast Agents
- Preclinical Ultrasound Contrast Agents
- Preclinical CT Contrast Agents
On the basis of reagents, the preclinical imaging market is segmented into preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents and preclinical CT contrast agents. The preclinical optical imaging reagents is sub-segmented into bioluminescent imaging reagents and fluorescent imaging reagents. The preclinical nuclear imaging reagents is sub-segmented into preclinical PET Tracers and preclinical SPECT probes. The preclinical MRI contrast agents is sub-segmented into gadolinium-based preclinical MRI contrast agents, iron-based preclinical MRI contrast agents and manganese-based preclinical MRI contrast agents. The preclinical CT contrast agents is sub-segmented into iodine-based preclinical CT contrast agents, barium-based preclinical CT contrast agents, gold nanoparticles and gastrografin-based preclinical CT contrast agents.
- Diagnostics Center
On the basis of end user, the preclinical imaging market is bifurcated into hospital, diagnostics center and others.
Preclinical Imaging Market Regional Analysis/Insights
The preclinical imaging market is analyzed and market size insights and trends are provided by country, modality, reagents and end user as referenced above.
The countries covered in the preclinical imaging market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the preclinical imaging market because of the presence of well-established players, technological advancements in the field of molecular imaging, rising market demand for non-invasive small-animal imaging techniques, and increased funding for preclinical research within the region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increasing funding to support preclinical researches as well presence of well-established market players within the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The preclinical imaging market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for preclinical imaging market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the preclinical imaging market. The data is available for historic period 2010-2020.
Competitive Landscape and Preclinical Imaging Market Share Analysis
The preclinical imaging market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to preclinical imaging market.
Some of the major players operating in the preclinical imaging market are
- PerkinElmer, Inc. (U.S.)
- Bruker (U.S.)
- FUJIFILM Holdings Corporation (Japan)
- Mediso Ltd. (Hungary)
- MILabs B.V. (Netherlands)
- MR Solutions (U.K.)
- LI-COR Inc., (U.S.)
- Aspect Imaging Ltd (Israel)
- TriFoil Imaging Inc., (U.S.)
- Danaher (US.)
- Siemens (Germany)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd., (Switzerland)
- Bio-Rad Laboratories, Inc (U.K)
- EKF Diagnostics (U.K)
- ?NIHON KOHDEN CORPORATION (Japan)
- Thermo Fisher Scientific Inc. (U.S.)
- Miltenyi Biotech (Germany)
Research Methodology : Global Preclinical Imaging Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-preclinical-imaging-market